Valdis Pīrāgs

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Diabetes Management, Cardiovascular Disease, Health Policy +10

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy

Angelika Bierhaus, Thomas Fleming, Stoyan Stoyanov et al. · Nature Medicine · 2012 · 488 citations

Neurophysiology, Pain Medicine, Medicine +13

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke

Robert Wilcox, Marie‐Germaine Bousser, D. J. Betteridge et al. · Stroke · 2007 · 473 citations